Cargando…
Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645458/ http://dx.doi.org/10.1186/2051-1426-3-S2-P156 |
| _version_ | 1782400817092886528 |
|---|---|
| author | Jackson, Doreen Qiao, Na Greene, Julia M Hale, Diane Berry, John Trappey, Alfred Vreeland, Timothy Clifton, Guy Ibrahim, Nuhad Toms, Annie Peoples, George E Mittendorf, Elizabeth A |
| author_facet | Jackson, Doreen Qiao, Na Greene, Julia M Hale, Diane Berry, John Trappey, Alfred Vreeland, Timothy Clifton, Guy Ibrahim, Nuhad Toms, Annie Peoples, George E Mittendorf, Elizabeth A |
| author_sort | Jackson, Doreen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645458 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46454582015-11-20 Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine Jackson, Doreen Qiao, Na Greene, Julia M Hale, Diane Berry, John Trappey, Alfred Vreeland, Timothy Clifton, Guy Ibrahim, Nuhad Toms, Annie Peoples, George E Mittendorf, Elizabeth A J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645458/ http://dx.doi.org/10.1186/2051-1426-3-S2-P156 Text en Copyright © 2015 Jackson et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Jackson, Doreen Qiao, Na Greene, Julia M Hale, Diane Berry, John Trappey, Alfred Vreeland, Timothy Clifton, Guy Ibrahim, Nuhad Toms, Annie Peoples, George E Mittendorf, Elizabeth A Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine |
| title | Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine |
| title_full | Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine |
| title_fullStr | Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine |
| title_full_unstemmed | Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine |
| title_short | Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine |
| title_sort | preliminary report of a clinical trial supporting the sequential use of an attenuated e39 peptide (e39') to optimize the immunologic response to the fbp (e39+gm-csf) vaccine |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645458/ http://dx.doi.org/10.1186/2051-1426-3-S2-P156 |
| work_keys_str_mv | AT jacksondoreen preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT qiaona preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT greenejuliam preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT halediane preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT berryjohn preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT trappeyalfred preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT vreelandtimothy preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT cliftonguy preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT ibrahimnuhad preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT tomsannie preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT peoplesgeorgee preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine AT mittendorfelizabetha preliminaryreportofaclinicaltrialsupportingthesequentialuseofanattenuatede39peptidee39tooptimizetheimmunologicresponsetothefbpe39gmcsfvaccine |